Adipositas und Diabetes

Jens Aberle; Anne Lautenbach; Svenja Meyhöfer; Sebastian M. Schmid; Lars Selig; Matthias Blüher

doi:10.1055/a-1179-2778

Diabetologie und Stoffwechsel, Table of Contents

Diabetologie und Stoffwechsel 2020; 15(S 01): S139-S147
DOI: 10.1055/a-1179-2778

DDG-Praxisempfehlung

Adipositas und Diabetes

Jens Aberle

¹Endokrinologie und Diabetologie, Universitäres Adipositas Centrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg

,

Anne Lautenbach

¹Endokrinologie und Diabetologie, Universitäres Adipositas Centrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg

,

Svenja Meyhöfer

²Institut für Endokrinologie & Diabetes, Universität zu Lübeck, Endokrinologie, Diabetologie und Stoffwechsel, Medizinische Klinik 1, UKSH – Campus Lübeck, Lübeck

,

Sebastian M. Schmid

²Institut für Endokrinologie & Diabetes, Universität zu Lübeck, Endokrinologie, Diabetologie und Stoffwechsel, Medizinische Klinik 1, UKSH – Campus Lübeck, Lübeck

,

Lars Selig

³Ernährungsteam/Ernährungsambulanz, Universitätsklinikum Leipzig – AoR, Leipzig

,

Matthias Blüher

⁴Klinik und Poliklinik für Endokrinologie und Nephrologie, Universitätsmedizin Leipzig, Leipzig

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Lindström J, Louheranta A, Mannelin M. et al Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003; 26: 3230-3236
2 Knowler WC, Barrett-Connor E, Fowler SE. et al Diabetes Prevention Program Research G: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
3 Lean ME, Powrie JK, Anderson AS. et al Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7: 228-233
4 Williamson DF, Thompson TJ, Thun M. et al Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-1504
5 Look ARG, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575
6 Eeg-Olofsson K, Cederholm J, Nilsson PM. et al Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009; 52: 65-73
7 Buse JB, Wexler DJ, Tsapas A. et al 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43: 487-493 . https://doi.org/10.2337/dci19-0066
8 Wang Z, Hoy WE. Waist circumference, body mass index, hip circumference and waist-to-hip ratio as predictors of cardiovascular disease in Aboriginal people. Eur J Clin Nutr 2004; 58: 888-893 . https://doi.org/10.1038/sj.ejcn.1601891
9 Pischon T, Boeing H, Hoffmann K. et al General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105-2120
10 Deutsche Gesellschaft für Ernährung (DGE) e.V. Vollwertig essen und trinken nach den 10 Regeln der DGE. 2017 https://www.dge.de/ernaehrungspraxis/vollwertige-ernaehrung/10-regeln-der-dge/
11 Deutsche Adipositas-Gesellschaft (DAG) e. V.; Deutsche Diabetes Gesellschaft (DDG); Deutsche Gesellschaft für Ernährung (DGE) e. V.; Deutsche Gesellschaft für Ernährungsmedizin (DGEM). Interdisziplinäre Leitlinie der Qualität S3 zur „Prävention und Therapie“ der Adipositas – Langfassung. Bundesärztekammer (BÄK); Kassenärztliche Bundesvereinigung (KBV); Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). 2014
12 Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311: 158-161 . https://doi.org/10.1136/bmj.311.6998.158
13 Evert AB, Dennison M, Gardner CD. et al Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care 2019; 42: 731-754
14 Reynolds AN, Akerman AP, Mann J. Dietary fibre and whole grains in diabetes management: Systematic review and meta-analyses. PLoS Med 2020; 17: e1003053
15 Landgraf R, Aberle J, Birkenfeld AL. et al Therapie des Typ-2-Diabetes. Diabetologie 2019; 14 (Suppl. 02) 144-167
16 Lean ME, Leslie WS, Barnes AC. et al Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541-551 . https://doi.org/10.1016/S0140-6736(17)33102-1
17 Gregg EW, Chen H, Wagenknecht LE. et al Association of an Intensive Lifestyle Intervention With Remission of Type 2 Diabetes. JAMA 2012; 308: 2489 . https://doi.org/10.1001/jama.2012.67929
18 Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes. – Langfassung. 2020 1. Auflage. Version 4.. https://doi.org/10.6101/AZQ/000213
19 Kay SJ, Fiatarone Singh MA. The influence of physical activity on abdominal fat: a systematic review of the literature. Obes Rev 2006; 7: 183-200 . https://doi.org/10.1111/j.1467-789X.2006.00250.x
20 Piercy KL, Troiano RP, Ballard RM. et al The Physical Activity Guidelines for Americans. JAMA 2018; 320: 2020 . https://doi.org/10.1001/jama.2018.14854
21 van Can J, Sloth B, Jensen CB. et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014;
22 Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial. JAMA 2015; 314 (07) 687-699 . doi:10.1001/jama.2015.9676
23 Pi-Sunyer X, Astrup A, Fujioka K. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373: 11-22 . doi: 10.1056/NEJMoa1411892
24 Golay A. Metformin and body weight. Int J Obes 2008; 32: 61-72 . doi:10.1038/sj.ijo.0803695
25 O’Neil PM, Birkenfeld AL, McGowan B. et al Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018; 392: 637-649 . doi:10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16
26 Frias JP, Nauck MA, Van J. et al Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 2018; 392: 2180-2193 . doi: 10.1016/S0140-6736(18)32260-8
27 Rubino F, Nathan DM, Eckel RH. et al Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 2016; 39: 861-877
28 S3-Leitlinie: Chirurgie der Adipositas und metabolischer Erkrankungen. 2018 https://www.awmf.org/uploads/tx_szleitlinien/088-001l_S3_Chirurgie-Adipositas-metabolische-Erkrankungen_2018-02.pdf
29 Flum DR, Belle SH, King WC. et al Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361: 445-445
30 Birkmeyer NJ, Dimick JB, Share D. et al Michigan Bariatric Surgery Collaborative. Hospital complication rates with bariatric surgery in Michigan. JAMA 2010; 304: 435-444
31 Aberle J, Reining F, Klinge A. et al Metformin After Bariatric Surgery – an Acid Problem. Exp Clin Endocrinol Diabetes 2012; 120: 152-153 . doi:10.1055/s-0031-1285911